Comparative analysis of immunophenotypic methods for the assessment of minimal residual disease in hairy cell leukemia

被引：0
|
作者：
Bengiò, R [1 ]
Narbaitz, MI [1 ]
Sarmiento, MA [1 ]
Palacios, MF [1 ]
Scolnik, MP [1 ]
机构：
[1] Acad Nacl Med, IIHEMA, Clin Hematol, Inst Invest Hematol Mariano R Castex, RA-1425 Buenos Aires, DF, Argentina
来源：
HAEMATOLOGICA | 2000年 / 85卷 / 11期
关键词：
MRD in hairy cell leukemia; pow cytometry; immunohistochemistry;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hairy cell leukemia patients in complete remission may have minimal residual disease (MRD), We performed flow cytometry (FCM) and immunohistochemistry (IHC) to detect MRD in 15 patients. FCM and IHC detected MRD+ in 64% and 46 % of the patients, respectively. MRD+ did not predict relapse.
引用
收藏
页码：1227 / 1229
页数：3
相关论文
共 50 条
  • [1] Eradication of minimal residual disease in hairy cell leukemia
    Ravandi, F
    Jorgensen, JL
    O'Brien, SM
    Verstovsek, S
    Koller, CA
    Faderl, S
    Giles, FJ
    Ferrajoli, A
    Wierda, WG
    Odinga, S
    Huang, XL
    Thomas, DA
    Freireich, EJ
    Jones, D
    Keating, MJ
    Kantarjian, HM
    BLOOD, 2006, 107 (12) : 4658 - 4662
  • [2] MINIMAL RESIDUAL DISEASE IN HAIRY CELL LEUKEMIA: DOES IT MATTER?
    Santos Carreira, A.
    Pinto, R.
    Carneiro, A.
    Principe, F.
    Guimaraes, J. E.
    HAEMATOLOGICA, 2015, 100 : 424 - 424
  • [3] BIOLOGICAL MARKERS AND MINIMAL RESIDUAL DISEASE IN HAIRY-CELL LEUKEMIA
    LAURIA, F
    RASPADORI, D
    BENFENATI, D
    RONDELLI, D
    PALLOTTI, A
    TURA, S
    LEUKEMIA, 1992, 6 : 149 - 151
  • [4] Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia.
    Kreitman, Robert J.
    Arons, Evgeny
    Still, Katherine
    Tallman, Martin S.
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    FitzGerald, David J. P.
    Pastan, Ira
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Left behind: should minimal residual disease be treated in hairy cell leukemia?
    Park, Jae H.
    Tallman, Martin S.
    LEUKEMIA & LYMPHOMA, 2014, 55 (05) : 971 - 972
  • [6] Immunophenotypic variations in hairy cell leukemia
    Chen, YH
    Tallman, MS
    Goolsby, C
    Peterson, L
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 125 (02) : 251 - 259
  • [7] Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy
    Thomas, Deborah A.
    Ravandi, Farhad
    Keating, Michael
    Kantarjian, Hagop M.
    LEUKEMIA & LYMPHOMA, 2009, 50 (01) : 27 - 31
  • [8] Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond Cladribine
    Bohn, Jan-Paul
    Dietrich, Sascha
    CANCERS, 2022, 14 (04)
  • [9] Minimal residual disease in hairy cell leukemia patients treated by BL22
    Arons, Evgeny
    Margulies, Inger
    Sorbara, Lynn
    Raffeld, Mark
    Stetler-Stevenson, Maryalice
    Pastan, Ira
    Kreitman, Robert J.
    CANCER RESEARCH, 2006, 66 (08)
  • [10] Minimal residual disease (MRD) in hairy cell leukemia (HCL):: Comparative detection by flow cytometry (FC) and immunohistochemistry (IHC).
    Sarmiento, M
    Scolnik, M
    Narbaitz, M
    Bengió, R
    BLOOD, 1999, 94 (10) : 284A - 284A
12345